Physician profile
Benjamin Dubin
NPI 1356495030
$17,147.90
in general payments reported to CMS, 2019-2025
40 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,335 · 2020: $1,633 · 2021: $2,632 · 2022: $2,134 · 2023: $2,055 · 2024: $2,589 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,151 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,151.36 |
| Education | $262.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,269.91 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $1,425.14 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,343.83 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $1,333.22 | 2019-2025 | |
| Amgen INC. | $1,020.76 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $987.85 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $925.47 | 2019-2025 | Adbry |
| Biofrontera INC. | $888.29 | 2019-2022 | |
| Janssen Biotech, INC. | $850.04 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $763.26 | 2019-2025 | |
| Ucb, INC. | $657.81 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $614.14 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $333.12 | 2019-2025 | |
| Galderma Laboratories, L.P. | $331.97 | 2019-2025 | Nemluvio, Aklief |
| Merz North America, INC. | $276.24 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Dubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.